Abstract
The focus of this chapter is to discuss how rational it can be to use multiple psychiatric medications in combinations to treat an individual patient and what are the basic principles to follow when doing so. This matter is put in the context of the rest of medicine where multiple medication use (MMU) can be based on a highly sophisticated rationale based on knowledge of the pathoetiology and pathophysiology of the illness being treated (e.g., Human Immuno Deficiency Virus- HIV) to a less sophisticated rationale because of limited understanding of the nature of the illness (e.g., bipolar disorder). In this regard, all diagnoses in medicine including psychiatry can be grouped into four hierarchical levels of understanding ranging from least sophisticated (symptomatic diagnoses) to the most sophisticated where pathoetiology and pathophysiology are known. Parenthetically, the goal of medicine as a field is to achieve the highest level of diagnostic sophistication possible to improve their ability to treat or alter the course of the disease. Unfortunately, most psychiatric diagnoses are still at the syndromic level and hence psychiatric medications are typically aimed at the alleviation of sign and symptoms of these disorders. Moreover, two related phenomena are increasing the frequency and complexity of MMU in psychiatry. The first is the increase in the number and types of psychiatric medications available: Since 1990, the Food and Drug Administration (FDA) approved almost 40 new psychotropic drugs to treat a variety of psychiatric illnesses. Second, the ability to rationally designed psychopharmaceuticals has further increase the potential, perhaps the need and perhaps the rationale behind psychiatric MMU. Nevertheless, until knowledge of the pathoetiology and pathophysiology of psychiatric diagnoses progresses beyond the syndromic level, the rationale underlying psychiatric MMU will remain more limited than is ideal.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Abbreviations
- AIDS:
-
Acquired Immuno Deficiency Syndrome
- APA:
-
American Psychiatric Association
- CO-MED:
-
Combining Medications to Enhance Depression Outcomes
- DSM-IV-TR:
-
Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision
- EPS:
-
Extra Pyramidal Symptoms
- HIV:
-
Human Immuno Deficiency Virus
- MMU:
-
Multiple Medication Use
- MPMU:
-
Multiple Psychiatric Medications Use
- QIDS-SR:
-
Quick Inventory of Depressive Symptomatology-Self Report
- SSRI:
-
Selective Serotonin Reuptake Inhibitors
- STAR*D:
-
Sequence Treatment Alternatives to Relieve Depression
- WHO:
-
World Health Organization
References
Pinel P (1806) A treatise on insanity. Classics of Medicine Library, Birmingham
Grand AL, Hogerzeil HV, Ruskamp FH (1999) Intervention research in rational use of drugs: a review. Health Policy Plann 14(2):89–102
Bjerrum L, Søgaard J, Hallas J, Kragstrup J (1999) Polypharmacy in general practice: differences between practitioners. Br J Gen Pract 49(440):195–198
Holm M, Olesen F (1989) Prescription of psychopharmaceuticals in general practice. 1. A registry study in the county of Arhus [Danish]. Ugeskr Laeger 151(34):2122–2126
Shad MU, Carmichael CA, Preskorn SH, Horst WD (1999) The nature and extent of polypharmacy in patients on antidepressants as a function of treatment setting. Clin Pharmacol Ther 65:183
Silkey B, Preskorn SH, Golbeck A et al (2005) Complexity of medication use in the Veterans affairs Healthcare System: Part II. Antidepressant use among young and older outpatients. J Psychiatr Pract 11:16–26
Goldman LS (2000) Comorbid medical illness in psychiatric patients. Curr Psychiatry Rep 2:256–263
Colley CA, Lucas LM (1993) Polypharmacy: the cure becomes the disease. J Gen Intern Med 8(5):278–283
Preskorn SH (1994) Antidepressant drug selection: criteria and options. J Clinical Psychiatry 55(suppl A):6–22, 23-,98–100
US Food and Drug Administration. www.fda.gov
Nichol MB, Stimmel GL, Lange SC (1995) Factors predicting the use of multiple psychotropic medications. J Clin Psychiatry 56:60–66
Mintz DC, Marcus SC, Druss BG et al (2004) Association of utilization management and treatment plan modifications among practicing US psychiatrists. Am J Psychiatry 161:1103–1109
Preskorn SH, Baker B (2002) The overlap of DSM-IV syndromes: potential implications for the practice of polypharmacology, psychiatric drug development and the human genome project. J Psychiatr Pract 8(3):170–177
Gulick RM, Ribaudo HJ, Shikuma CM et al (2006) Three- vs four-drug antiretroviral regimens for the initial treatment of HIV-1 infection: a randomized controlled trial. JAMA 296(7):769–781
Medical Economics (1995) Physicians’ desk reference, 49th edn. Medical Economics, Philadelphia, pp 959–963
Jozefowicz RF, Berg M, Dimitsopulos T et al (1993) Current therapy. In: Joynt RJ (ed) Clinical neurology, vol 1. JB Lippincott, Philadelphia
McDowell F, Cedarbaum JM (1993) The extrapyramidal system and disorder of movement. In: Joynt RJ (ed) Clinical neurology, vol 3. JB Lippincott, Philadelphia
American Psychiatric Association (2000) Diagnostic and statistical manual of mental disorders, 4th edn, text revision. American Psychiatric Association, Washington, DC
Rush AJ, Trivedi MH, Stewart JW et al (2011) Combining medications to enhance depression outcomes (CO-MED): acute and long term outcomes of a single-blind randomized study. Am J Psychiatry 168(7):689–701
Carpenter LL, Yasmin S, Price LH (2002) A double-blind, placebo controlled study of antidepressant augmentation with mirtazapine. Biol Psychiatry 51:183–188
Stewart JW, McGrath PI, Deliyannides RA et al (2009) Does dual antidepressant therapy as initial treatment hasten and increase remission from depression? J Psychiatr Pract 15:337–345
Blier P, Ward HE, Tremblay P et al (2010) Combination of antidepressant medications from treatment initiation for major depressive disorder: a double-blind randomized study. Am J Psychiatry 167:281–288
McInnes GT, Brodie MJ (1988) Drug interactions that matter: a critical reappraisal. Drugs 36:83–110
Tune LE (2001) Anticholinergic effects of medications in elderly patients. J Clin Psychiatry 62(21):11–14
Callahan AM, Fava M, Rosenbaum JF (1993) Drug interactions in psychopharmacology. Psychiatr Clin North Am 16:647–671
Preskorn SH (2012) Clinically important differences in the pharmacokinetics of the ten newer “atypical” antipsychotics: Part I. J Psych Practice 18(3):199–204
Artigas F, Perez V, Alvarez E (1994) Pidolol induces a rapid improvement of depressed patients treated with serotonin reuptake inhibitors. Arch Gen Psychiatry 51:248–251
Kalia R, Mittal MS, Preskorn SH (2011) Vilazodone for major depressive disorder. Current Psychiatry 10(4):84–88
Gerner RH (1993) Treatment of acute mania. Psychiatr Clin North Am 16:443–460
Hyttel J (1993) Comparative pharmacology of selective serotonin reuptake inhibitors (SSRIs). Nord J Psychiatry 47(suppl 30):5–12
Trivedi MH, Fava M, Wisnieski SR et al (2006) Medication augmentation after the failure of SSRIs for depression. N Engl J Med 354(12):1243–1252
Nierenberg AA, Fava M, Trivedi MH et al (2006) A comparison of lithium and T3 augmentation following two failed medication treatments for depression: a STAR*D report. Am J Psychiatry 163(9):1519–1530
Janicak PG, Davis JM, Preskorn SH et al (2001) Principles and practices of psychopharmacotherapy, 3rd edn. Williams and Wilkins, Baltimore
Hendrickse W, Roffwarg H, Grannemann B et al (1994) The effects of fluoxetine on the polysomnogram of depressed outpatients: a pilot study. Neuropsychopharmacology 10:85–91
TherapeuticsDaily. http://www.therapeuticsdaily.com/news/article.cfm. Accessed 1 May 2012
Routledge PA (1986) The plasma protein binding of basic drugs. Br J Clin Pharmacol 22:499–506
Thurmann PA, Hompesch BC (1998) Influence of gender on the pharmacokinetics and pharmacodynamics of drugs. Int J Clin Pharmacol Ther 36:586–590
Muller-Oerlinghausen B, Retzow A, Henn FA et al. (European Valproate Mania Study Group) (2000) Valproate as an adjunct to neuroleptic medication for the treatment of acute episodes of mania: a prospective, randomized, double-blind, placebo-controlled, multicenter study. J Clin Psychopharmacol 20:195–203
Yatham LN (2000) Safety and efficacy of risperidone as combination therapy for the manic phase of bipolar disorder: preliminary findings of a randomized double blind study. Int J Neuropsychopharmacol 3(suppl 1):S142
Pollack MH, Simon NM, Worthington JJ et al (2003) Combined paroxetine and clonazepam treatment strategies compared to paroxetine monotherapy for panic disorder. J Psychopharmacol 17:276–282
Goddard AW, Brouette T, Almai A et al (2001) Early coadministration of clonazepam with sertraline for panic disorder. Arch Gen Psychiatry 58:681–686
Acknowledgments
To my wife Naila, and my sons Maaz and Faraz
For your love and support
In memory of my parents, Mohammed and Raisa
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2013 Springer Science+Business Media Dordrecht
About this chapter
Cite this chapter
Khan, A.Y., Preskorn, S.H. (2013). Multiple Psychiatric Medications Use in Psychiatry: How Rational Can It Be?. In: Ritsner, M. (eds) Polypharmacy in Psychiatry Practice, Volume I. Springer, Dordrecht. https://doi.org/10.1007/978-94-007-5805-6_1
Download citation
DOI: https://doi.org/10.1007/978-94-007-5805-6_1
Published:
Publisher Name: Springer, Dordrecht
Print ISBN: 978-94-007-5804-9
Online ISBN: 978-94-007-5805-6
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)